224 related articles for article (PubMed ID: 12769603)
1. Molecular and cellular mechanism of glutamate receptors in relation to amyotrophic lateral sclerosis.
Iwasaki Y; Ikeda K; Kinoshita M
Curr Drug Targets CNS Neurol Disord; 2002 Oct; 1(5):511-8. PubMed ID: 12769603
[TBL] [Abstract][Full Text] [Related]
2. Glutamate, excitotoxicity and amyotrophic lateral sclerosis.
Shaw PJ; Ince PG
J Neurol; 1997 May; 244 Suppl 2():S3-14. PubMed ID: 9178165
[TBL] [Abstract][Full Text] [Related]
3. Excitotoxicity and amyotrophic lateral sclerosis.
Van Damme P; Dewil M; Robberecht W; Van Den Bosch L
Neurodegener Dis; 2005; 2(3-4):147-59. PubMed ID: 16909020
[TBL] [Abstract][Full Text] [Related]
4. Riluzole and ALS therapy.
Hugon J
Wien Med Wochenschr; 1996; 146(9-10):185-7. PubMed ID: 8873431
[TBL] [Abstract][Full Text] [Related]
5. Update on the glutamatergic neurotransmitter system and the role of excitotoxicity in amyotrophic lateral sclerosis.
Heath PR; Shaw PJ
Muscle Nerve; 2002 Oct; 26(4):438-58. PubMed ID: 12362409
[TBL] [Abstract][Full Text] [Related]
6. Differential cortico-motoneuron vulnerability after chronic mitochondrial inhibition in vitro and the role of glutamate receptors.
Van Westerlaak MG; Joosten EA; Gribnau AA; Cools AR; Bär PR
Brain Res; 2001 Dec; 922(2):243-9. PubMed ID: 11743956
[TBL] [Abstract][Full Text] [Related]
7. Knocking down metabotropic glutamate receptor 1 improves survival and disease progression in the SOD1(G93A) mouse model of amyotrophic lateral sclerosis.
Milanese M; Giribaldi F; Melone M; Bonifacino T; Musante I; Carminati E; Rossi PI; Vergani L; Voci A; Conti F; Puliti A; Bonanno G
Neurobiol Dis; 2014 Apr; 64():48-59. PubMed ID: 24361555
[TBL] [Abstract][Full Text] [Related]
8. Aberrant control of motoneuronal excitability in amyotrophic lateral sclerosis: excitatory glutamate/D-serine vs. inhibitory glycine/gamma-aminobutanoic acid (GABA).
Sasabe J; Aiso S
Chem Biodivers; 2010 Jun; 7(6):1479-90. PubMed ID: 20564566
[TBL] [Abstract][Full Text] [Related]
9. A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade?
Bellingham MC
CNS Neurosci Ther; 2011 Feb; 17(1):4-31. PubMed ID: 20236142
[TBL] [Abstract][Full Text] [Related]
10. Excitatory amino acid receptors and neurodegeneration.
Doble A
Therapie; 1995; 50(4):319-37. PubMed ID: 7482387
[TBL] [Abstract][Full Text] [Related]
11. Potential treatment of amyotrophic lateral sclerosis with gabapentin: a hypothesis.
Welty DF; Schielke GP; Rothstein JD
Ann Pharmacother; 1995 Nov; 29(11):1164-7. PubMed ID: 8573965
[TBL] [Abstract][Full Text] [Related]
12. Riluzole: what it does to spinal and brainstem neurons and how it does it.
Cifra A; Mazzone GL; Nistri A
Neuroscientist; 2013 Apr; 19(2):137-44. PubMed ID: 22596264
[TBL] [Abstract][Full Text] [Related]
13. In-vivo effects of knocking-down metabotropic glutamate receptor 5 in the SOD1
Bonifacino T; Cattaneo L; Gallia E; Puliti A; Melone M; Provenzano F; Bossi S; Musante I; Usai C; Conti F; Bonanno G; Milanese M
Neuropharmacology; 2017 Sep; 123():433-445. PubMed ID: 28645622
[TBL] [Abstract][Full Text] [Related]
14. Serotonergic mechanisms in amyotrophic lateral sclerosis.
Sandyk R
Int J Neurosci; 2006 Jul; 116(7):775-826. PubMed ID: 16861147
[TBL] [Abstract][Full Text] [Related]
15. Glutamate transporters and the excitotoxic path to motor neuron degeneration in amyotrophic lateral sclerosis.
Foran E; Trotti D
Antioxid Redox Signal; 2009 Jul; 11(7):1587-602. PubMed ID: 19413484
[TBL] [Abstract][Full Text] [Related]
16. Excitotoxic mechanisms in the pathogenesis of amyotrophic lateral sclerosis.
Rothstein JD
Adv Neurol; 1995; 68():7-20; discussion 21-7. PubMed ID: 8787245
[TBL] [Abstract][Full Text] [Related]
17. Excess glutamate secreted from astrocytes drives upregulation of P-glycoprotein in endothelial cells in amyotrophic lateral sclerosis.
Mohamed LA; Markandaiah SS; Bonanno S; Pasinelli P; Trotti D
Exp Neurol; 2019 Jun; 316():27-38. PubMed ID: 30974102
[TBL] [Abstract][Full Text] [Related]
18. Decrease in glial glutamate transporter variants and excitatory amino acid receptor down-regulation in a murine model of ALS-PDC.
Wilson JM; Khabazian I; Pow DV; Craig UK; Shaw CA
Neuromolecular Med; 2003; 3(2):105-18. PubMed ID: 12728193
[TBL] [Abstract][Full Text] [Related]
19. Riluzole is a potent drug to protect neonatal rat hypoglossal motoneurons in vitro from excitotoxicity due to glutamate uptake block.
Cifra A; Nani F; Nistri A
Eur J Neurosci; 2011 Mar; 33(5):899-913. PubMed ID: 21324003
[TBL] [Abstract][Full Text] [Related]
20. Prospects for the pharmacotherapy of amyotrophic lateral sclerosis : old strategies and new paradigms for the third millennium.
Festoff BW; Suo Z; Citron BA
CNS Drugs; 2003; 17(10):699-717. PubMed ID: 12873154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
